Johns Hopkins

The trials here

What the 71 trials at this site are about, from their registry records.

Conditions

• Prostate cancer7 trials
• Atrial fibrillation4 trials
• Childhood cancers4 trials
• Colorectal cancer3 trials
• COPD3 trials
• Cystic fibrosis3 trials
• Lung cancer3 trials
• Multiple sclerosis3 trials
• Ovarian cancer3 trials
• Pancreatic cancer3 trials
• Parkinson disease3 trials
• Sarcoma3 trials
• and 43 more

Phase

• Phase 220 trials
• Phase 310 trials
• Phase 15 trials
• Phase 1/25 trials
• Early phase 11 trial
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed21 trials
• Active, not recruiting20 trials
• Recruiting20 trials
• Not yet recruiting3 trials
• Withdrawn3 trials
• Terminated2 trials
• Enrolling by invitation1 trial
• Suspended1 trial

Lead sponsor

• Johns Hopkins University12 trials
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3 trials
• AstraZeneca2 trials
• Biosense Webster, Inc.2 trials
• Fox Chase Cancer Center2 trials
• and 44 more

Running trials

• Not yet recruiting

  Remote Monitoring in Progressive Supranuclear Palsy (PSP)

  NCT04753320· Massachusetts General Hospital· Source

  Contact: AJ Hall

• Not yet recruiting

  WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor).

  NCT07430605· LASARRUS Clinic and Research Center· Source

  Contact: Edward S Chen, MD

• Recruiting

  Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

  NCT07175441· Phase 2· Riboscience, LLC.· Source

  Contact: Riboscience Clinical Trials

• Recruiting

  A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV

  NCT07392372· Phase 1· BioNTech SE· Source

• Recruiting

  Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

  NCT07053917· Phase 1· Johns Hopkins University· Source

  Contact: Steven R Zeiler, M.D., Ph.D.

• Recruiting

  Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

  NCT07349537· Phase 1· Revolution Medicines, Inc.· Source

  Contact: Revolution Medicines Study Director

• Active, not recruiting

  Study of COYA 302 for the Treatment of ALS

  NCT07161999· Phase 2/3· Coya Therapeutics· Source

• Recruiting

  First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

  NCT06934538· Phase 1/2· Brenus Pharma· Source

  Contact: Eric Christenson, MD

• Recruiting

  Effectiveness of the WearME System for COPD Severity and Respiratory Function

  NCT06751537· LASARRUS Clinic and Research Center· Source

  Contact: Chathurangi Pathiravasan, PhD

• Recruiting

  A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

  NCT06610682· Early phase 1· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

  Contact: Karisa Schreck, MD

• Active, not recruiting

  Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT06625320· Phase 3· Revolution Medicines, Inc.· Source

• Active, not recruiting

  A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

  NCT06455098· Biosense Webster, Inc.· Source

• Recruiting

  Multi-Center Clean Air Randomized Controlled Trial in COPD

  NCT06376994· Phase 3· JHSPH Center for Clinical Trials· Source

  Contact: Wendy Lorizio

• Active, not recruiting

  AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

  NCT06029660· Shape Memory Medical, Inc.· Source

• Active, not recruiting

  Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

  NCT05824728· Phase 2· Johns Hopkins University· Source

• Recruiting

  Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

  NCT05636618· Phase 1/2· Perspective Therapeutics· Source

  Contact: Seyed Ali Mosallaie, MD (principal investigator)

• Enrolling by invitation

  Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

  NCT06167642· Johns Hopkins University· Source

• Active, not recruiting

  Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

  NCT05683691· Francis Medical Inc.· Source

• Recruiting

  Estrogen Supplementation and Bone Health in Women With CF

  NCT05704036· Phase 4· Johns Hopkins University· Source

  Contact: Cynthia Wang

• Active, not recruiting

  Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

  NCT05462145· Kardium Inc.· Source

• Recruiting

  Abatacept in Immune Checkpoint Inhibitor Myocarditis

  NCT05335928· Phase 3· Massachusetts General Hospital· Source

  Contact: Joban Vaishnav

• Active, not recruiting

  CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

  NCT05306288· Delfi Diagnostics Inc.· Source

• Recruiting

  Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

  NCT04797286· Phase 2· Johns Hopkins University· Source

  Contact: Stephen Mathai, MD

• Active, not recruiting

  SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

  NCT04803877· Phase 2· Sarcoma Alliance for Research through Collaboration· Source

• Active, not recruiting

  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT04691804· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Recruiting

  Parkinson's Foundation PD GENEration Genetic Registry

  NCT04994015· Parkinson's Foundation· Source

  Contact: Shamera Willoughby

• Active, not recruiting

  Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

  NCT04443348· Phase 2· Laura M. Spring, MD· Source

• Active, not recruiting

  Natural Versus Programmed Frozen Embryo Transfer (NatPro)

  NCT04551807· Phase 3· JHSPH Center for Clinical Trials· Source

• Recruiting

  A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

  NCT04503265· Phase 1/2· AtlasMedx, Incorporated· Source

  Contact: Bonnie Wettersten, MS

• Recruiting

  EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

  NCT03266653· Phase 2· New York Medical College· Source

  Contact: Kenneth Cooke, MD

• Recruiting

  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

  NCT04045665· Phase 3· Icahn School of Medicine at Mount Sinai· Source

  Contact: Zyriah Robinson

• Active, not recruiting

  International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

  NCT04496687· SCAD Alliance· Source

• Recruiting

  Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

  NCT03266640· Phase 2· New York Medical College· Source

  Contact: Kenneth Cooke, MD

• Active, not recruiting

  Spinraza in Adult Spinal Muscular Atrophy

  NCT03709784· Washington University School of Medicine· Source

• Recruiting

  The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

  NCT03142152· Cardiac Dimensions, Inc.· Source

  Contact: Zyriah Robinson

• Active, not recruiting

  Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

  NCT03172754· Phase 1/2· Fox Chase Cancer Center· Source

• Recruiting

  Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

  NCT03141021· Washington University School of Medicine· Source

  Contact: Christine Pratilas, M.D.

• Active, not recruiting

  Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

  NCT02603341· Abramson Cancer Center at Penn Medicine· Source

• Active, not recruiting

  Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

  NCT01874353· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

  NCT01844986· Phase 3· AstraZeneca· Source

• Recruiting

  Functional Assessment in Liver Transplantation

  NCT03228290· University of California, San Francisco· Source

  Contact: Betsy King, MD

• Active, not recruiting

  Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

  NCT00999804· Phase 2· Baylor Breast Care Center· Source

• Recruiting

  A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  NCT01351545· Center for International Blood and Marrow Transplant Research· Source

  Contact: Allen Chen, MD, PhD

• Active, not recruiting

  Biobank For MS And Other Demyelinating Diseases

  NCT00445367· Accelerated Cure Project for Multiple Sclerosis· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD3 recruiting
• Childhood cancers2 recruiting
• Colorectal cancer2 recruiting
• Pancreatic cancer2 recruiting
• Parkinson disease2 recruiting
• Sarcoma2 recruiting
• Stroke2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Alzheimer disease1 recruiting
• Aplastic anaemia1 recruiting
• Atrial fibrillation1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Cystic fibrosis1 recruiting
• Cytomegalovirus infection1 recruiting
• Heart failure1 recruiting
• HIV1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Lung cancer1 recruiting
• Meningioma1 recruiting
• Multiple myeloma1 recruiting
• Multiple sclerosis1 recruiting
• Multiple system atrophy1 recruiting
• Myocarditis1 recruiting
• Neuroendocrine tumours1 recruiting
• Osteoporosis1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

  NCT07108153· Phase 2· Sionna Therapeutics Inc.· Source

• Completed

  Safe Spaces 4 Sexual Health

  NCT07133555· Johns Hopkins University· Source

• Completed

  Delivering a Digital Health Intervention to Improve Food Access and Dietary Quality Among Adults With Hypertension

  NCT06743191· Johns Hopkins University· Source

• Withdrawn

  Clinical Trial of AGB101 for Mild Cognitive Impairment

  NCT05986721· Phase 2· AgeneBio· Source

• Terminated

  Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye

  NCT06411132· Dompé Farmaceutici S.p.A· Source

• Completed

  A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

  NCT06292923· Phase 2· Tiziana Life Sciences LTD· Source

• Terminated

  ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

  NCT05824559· Phase 1· MEI Pharma, Inc.· Source

• Completed

  IS-002 Phase 2 Prostate Cancer Study

  NCT05946603· Phase 2· Intuitive Surgical· Source

• Withdrawn

  Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

  NCT05472623· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  iTBS in Bipolar I Depression

  NCT05375214· Johns Hopkins University· Source

• Completed

  Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

  NCT05495243· Phase 2· Renovion, Inc.· Source

• Completed

  Ablation at Virtual-hEart pRedicted Targets for VT

  NCT03536052· Johns Hopkins University· Source

• Withdrawn

  177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

  NCT04315246· Phase 1/2· Y-mAbs Therapeutics· Source

• Completed

  An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

  NCT05477524· Phase 3· Pfizer· Source

• Completed

  Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System

  NCT05293639· Biosense Webster, Inc.· Source

• Completed

  Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

  NCT05220501· Sunnybrook Health Sciences Centre· Source

• Completed

  A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

  NCT04075916· Phase 2· University of Pennsylvania· Source

• Completed

  A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

  NCT04504812· Phase 3· Johns Hopkins University· Source

• Completed

  Cognitive Behavioral Therapy and Real-Time Pain Management Intervention for Sickle Cell Via Mobile Applications

  NCT04419168· University of Pittsburgh· Source

• Completed

  RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

  NCT04037358· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH

  NCT04610788· Johns Hopkins University· Source

• Completed

  Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis

  NCT03098563· Phase 2· Johns Hopkins University· Source

• Completed

  Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

  NCT02289209· Phase 2· Dan Zandberg· Source

• Completed

  Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

  NCT02710734· Phase 2· Fox Chase Cancer Center· Source

• Completed

  Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

  NCT02228681· Phase 2· GOG Foundation· Source

• Completed

  Effectiveness of Open and Robotic Prostatectomy

  NCT01325506· Beth Israel Deaconess Medical Center· Source